Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATH 434

Next Previous
Drug Profile

ATH 434

Alternative Names: ATH-434; PBT 434

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prana Biotechnology
  • Developer Alterity Therapeutics
  • Class Amines; Antiparkinsonians; Chlorinated hydrocarbons; Neuroprotectants; Quinazolinones; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Iron chelating agents; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple system atrophy
  • Phase I Parkinson's disease

Most Recent Events

  • 17 Apr 2024 Efficacy data from the phase II bioMUSE trial in Multiple system atrophy were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting (AAN-2024)
  • 17 Apr 2024 Pharmacodynamics data from preclinical studies in Parkinson's disease were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting (AAN-2024)
  • 04 Dec 2023 Pharmacodynamics data from a preclinical trial in Parkinson's disease released by Alterity Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top